January 14, 2005 After listening to companies make their business cases at the recent JPMorgan Healthcare Conference, we believe the following list to be the key biotech approvals in 2004. These products will drive stock prices for their parent companies in 2005. The story lists only noteworthy approvals, and it also references articles we wrote at the time of the approval.
